# A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing 

Source: https://onco.cc/trials/nct06956690/  
OnCo record `nct06956690` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ENV-501 in melanoma and non-small-cell lung cancer, run by Hummingbird Bioscience, now recruiting.

## Summary

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors is a phase 1/2 interventional study registered as NCT06956690 by Hummingbird Bioscience, with 180 participants planned, started 2025-12-17 and due to reach its primary completion in 2027-07. Interventions recorded: ENV-501. Conditions listed: Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06956690
- Phase: 1/2
- Setting: A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors
- Sponsor: Hummingbird Bioscience
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06956690: https://clinicaltrials.gov/study/NCT06956690

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [ENV-501](https://onco.cc/drugs/env-501/)

---
JSON: https://onco.cc/api/v1/entities/nct06956690.json